Churchill Capital Corp XI (CCXI)vsHarvard Ave Acquisition Corporation Class A Ordinary Share (HAVA)
CCXI
Churchill Capital Corp XI
$15.55
-4.19%
FINANCIAL SERVICES · Cap: $1.06B
HAVA
Harvard Ave Acquisition Corporation Class A Ordinary Share
$10.12
+0.20%
FINANCIAL SERVICES · Cap: $209.00M
Smart Verdict
WallStSmart Research — data-driven comparison
HAVA leads profitability with a 0.0% profit margin vs 0.0%. HAVA earns a higher WallStSmart Score of 30/100 (F).
CCXI
Avoid24
out of 100
Grade: F
HAVA
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 805 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 4.7% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : CCXI
CCXI has a balanced fundamental profile.
Bull Case : HAVA
The strongest argument for HAVA centers on Return on Equity, Debt/Equity.
Bear Case : CCXI
The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : HAVA
The primary concerns for HAVA are Revenue Growth, EPS Growth, Market Cap. A P/E of 112.2x leaves little room for execution misses.
Key Dynamics to Monitor
HAVA is growing revenue faster at 0.0% — sustainability is the question.
HAVA generates stronger free cash flow (8,488), providing more financial flexibility.
Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HAVA scores higher overall (30/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Churchill Capital Corp XI
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Harvard Ave Acquisition Corporation Class A Ordinary Share
FINANCIAL SERVICES · SHELL COMPANIES · USA
Harvard Ave Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company is headquartered in Seoul, South Korea.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?